Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05557162 · ClinicalTrials.gov registry record · NA
Artificial Intelligence Enhanced ECG to Detect Cardiac Amyloidosis
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 20,143
- Enrollment target
NCT05557162: Completed NA study, sponsored by Mayo Clinic.
NCT05557162 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 20,143 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (1336% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05557162, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 20,143 participants
- Enrollment target
Study Summary
The purpose of this study is to assess a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis of cardiac amyloidosis (CA).
Primary Outcome
The number of patients diagnosed with cardiac amyloidosis in cardiology and hematology practices will be compared between those providers undergoing the AI ECG intervention to those randomized to standard practice arm
Interventions
- OTHER AI ECG Amyloid algorithm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,143 participants |
| Start Date | 2023-06-19 |
| Est. Completion | 2025-07-23 |
| Phase | NA |
What the finished NCT05557162 record still lists
NCT05557162 is an interventional study that assigns participants to a tested intervention. Its 20,143 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (1336% higher).
The record links to 0 conditions, and to 1 intervention - of which AI ECG Amyloid algorithm is the first listed.
NCT05557162 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05557162 about?
NCT05557162 is a clinical study titled "Artificial Intelligence Enhanced ECG to Detect Cardiac Amyloidosis". The purpose of this study is to assess a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis of cardiac amyloidosis (CA).
What is the current status of trial NCT05557162?
This trial is currently completed. It is a NA study. The enrollment target is 20,143 participants. The study started on 2023-06-19. Estimated completion is 2025-07-23.
What interventions are being tested in trial NCT05557162?
The interventions under investigation include: AI ECG Amyloid algorithm (OTHER).
Who is sponsoring clinical trial NCT05557162?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05557162's enrollment target sits among peer trials
20,143 11th of 2000 higher than 1,990 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
- NCT00830557 · 20,000 participants
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
- NCT00900471 · 20,000 participants
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
- NCT02735707 · 20,000 participants · Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI